Everything below concerns lyophilisation. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-01-30. Numbers and descriptions here follow the published literature rather than marketing material.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
| Property | Value | Notes |
|---|---|---|
| Storage temperature (solid) | -20 °C or below | Freezer storage with desiccant |
| Solubility | Soluble in water and aqueous buffer | Careful dissolution needed at higher concentrations |
| Appearance | White to off-white lyophilised powder | Visual inspection for discolouration |
| Primary analytical method | Reversed-phase HPLC with UV detection | Paired with mass spectrometry for identity |
| Common synonyms | Triple-agonist peptide; GLP-1/GIP/glucagon agonist | Naming varies across the literature |
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
===== Cuba ===== On 15 September, Lula and four of his cabinet minister visited Cuba where they met with Cuban president and first secretary of the Communist Party of Cuba Miguel Díaz-Canel. During his visit, Lula also attended a summit of the Group of 77 plus China in Havana where he lamented the United States embargo against Cuba stating that the island "is the victim of an illegal economic embargo, Brazil is against any unilateral coercive measure". Lula also criticized the inclusion of Cuba in the US list of states sponsors of terrorism.
== External links == PiHKAL ("Phenethylamines I Have Known And Loved") by Alexander "Sasha" Shulgin (1991) DOx - PsychonautWiki Category: DOX - Tripsitter DOx (psychedelics) - Wikipedia Massviews Analysis (Wikipedia Page Views of Individual DOx Drugs)
A team led by Enrico Fermi in 1934 found that bombarding uranium with neutrons produces beta rays (electrons or positrons from the elements produced; see beta particle). The fission products were at first mistaken for new elements with atomic numbers 93 and 94, which the Dean of the Sapienza University of Rome, Orso Mario Corbino, named ausenium and hesperium, respectively. The experiments leading to the discovery of uranium's ability to fission (break apart) into lighter elements and release binding energy were conducted by Otto Hahn and Fritz Strassmann in Hahn's laboratory in Berlin. Lise Meitner and her nephew, physicist Otto Robert Frisch, published the physical explanation in February 1939 and named the process "nuclear fission". Soon afterward, Fermi hypothesized that fission of uranium might release enough neutrons to sustain a fission reaction. Confirmation of this hypothesis came in 1939, and later work found that on average about 2.5 neutrons are released by each fission of uranium-235. Fermi urged Alfred O. C. Nier to separate uranium isotopes for determination of the fissile component, and on 29 February 1940, Nier used an instrument he built at the University of Minnesota to separate the world's first uranium-235 sample in the Tate Laboratory. Using Columbia University's cyclotron, John Dunning confirmed the sample to be the isolated fissile material on 1 March. Further work found that the far more common uranium-238 isotope can be transmuted into plutonium, which, like uranium-235, is also fissile by thermal neutrons.
Sources: en.wikipedia.org
=== Operations === The LIMS is an evolving concept, with new features and functionality being added often. As laboratory demands change and technological progress continues, the functions of a LIMS will likely also change. Despite these changes, a LIMS tends to have a base set of functionality that defines it. That functionality can roughly be divided into five laboratory processing phases, with numerous software functions falling under each: (1) the reception and log in of a sample and its associated customer data, (2) the assignment, scheduling, and tracking of the sample and the associated analytical workload, (3) the processing and quality control associated with the sample and the utilized equipment and inventory, (4) the storage of data associated with the sample analysis, (5) the inspection, approval, and compilation of the sample data for reporting and/or further analysis. There are several pieces of core functionality associated with these laboratory processing phases that tend to appear in most LIMS:
== History == Esketamine was introduced for medical use as an anesthetic in Germany in 1997, and was subsequently marketed in other countries. In addition to its anesthetic effects, the medication showed properties of being a rapid-acting antidepressant, and was subsequently investigated for use as such. Esketamine received a breakthrough designation from the FDATooltip Food and Drug Administration for treatment-resistant depression (TRD) in 2013 and major depressive disorder (MDD) with accompanying suicidal ideation in 2016. In November 2017, it completed phase III clinical trials for treatment-resistant depression in the United States. Johnson & Johnson filed a Food and Drug Administration (FDA) New Drug Application (NDA) for approval on 4 September 2018; the application was endorsed by an FDA advisory panel on 12 February 2019, and on 5 March 2019, the FDA approved esketamine, in conjunction with an oral antidepressant, for the treatment of depression in adults. In August 2020, it was approved by the U.S. Food and Drug Administration (FDA) with the added indication for the short-term treatment of suicidal thoughts. Since the 1980s, closely associated ketamine has been used as a club drug also known as "Special K" for its trip-inducing side effects.
Vehicle location data: Real-time GPS tracking for continuous visibility of the asset's location. Temperature monitoring: Data from multiple sensors placed inside the trailer or container to ensure uniform temperature distribution. Reefer unit status: Critical operational data such as the temperature setpoint, return air temperature, operating mode (e.g., continuous vs. start/stop), and any active alarm codes from the refrigeration unit. Door sensors: Alerts that are triggered whenever cargo doors are opened or closed, helping to monitor security and prevent unnecessary temperature excursions.
Sources: en.wikipedia.org
== GAR == Glycineamide ribonucleotide Glutathione amide reductase, an enzyme Grand Army of the Republic, US Civil War veterans organization; also Grand Army of the Republic (disambiguation) lists other organizations with that name Garrison Hall, University of Texas at Austin Great American Recreation, the company owned and operated Action Park in New Jersey, US until 1996 IOC code for artistic gymnastics at the Summer Olympics
According to Mediapart, the text was "mostly relayed by far-right activists, press outlets or personalities". Dora Moutot and Marguerite Stern later launched "femellism", a movement which according to Arrêt sur images is rejected by many feminists "for its transphobia". According to its report, the movement adheres to conspiracy theories about the "funding of the trans lobby" and remains close to ultraconservative and far-right ideology. The two activists rejected these accusations and characterized femellism as a fight "against the oppressions that women suffer because of their sex". Libération criticizes the two activists for ideological connections and common obsessions with the activists of La Manif pour tous and the far-right. Marguerite Stern later lent her support to a well-known figure of the far-right, Julien Rochedy, a masculinist and former national director of National Rally's youth group between 2012 and 2014. In September 2024, she gave a lecture at the Institut de sciences sociales économiques et politiques, a group founded by Marion Maréchal, a far-right political figure. Dora Moutot and Marguerite Stern were welcomed shortly after by LREM deputies Caroline Yadan and Aurore Bergé, which led to protests from two other LREM elected officials, Pierre Karleskind and Raphaël Gérard, the latter denouncing Carloine Yadan's "vocabulary which makes echo of the hateful speeches heard in Poland or Hungary". Shortly after this meeting Aurore Bergé tabled an amendment to remove language inclusive of trans men from a bill designed to enshrine access to abortion.
A direct relativistic effect is that as the atomic numbers of elements increase, the innermost electrons begin to revolve faster around the nucleus as a result of an increase of electromagnetic attraction between an electron and a nucleus. Similar effects have been found for the outermost s orbitals (and p1/2 ones, though in dubnium they are not occupied): for example, the 7s orbital contracts by 25% in size and is stabilized by 2.6 eV. A more indirect effect is that the contracted s and p1/2 orbitals shield the charge of the nucleus more effectively, leaving less for the outer d and f electrons, which therefore move in larger orbitals. Dubnium is greatly affected by this: unlike the previous group 5 members, its 7s electrons are slightly more difficult to extract than its 6d electrons.
More sanctions were eased on 13 February, with the issue of two licenses allowing international companies to operate oil and gas projects in Venezuela and to negotiate contracts. Payments go to a US-controlled foreign government deposit fund. US energy secretary that visited the Venezuela in February, said that oil sales have hit $1 billion since January and would hit another $5 billion in months. The US Treasury Department indicated that companies working of Venezuelan oil trade have to pay local taxes, permits and fees to the government of Venezuela, while royalties and federal taxes must be paid into a fund managed by the United States. During the 2026 State of the Union Address, Trump announced that the US "just received from our new friend and partner, Venezuela, more than 80 million barrels of oil." According to the Reuters in February, the Venezuelan oil ministry cancelled 19 contracts with private companies on oil and gas in Venezuela signed under the government of Nicolás Maduro. Venezuelan and US administrations are reviewing the credentials of the companies that signed them. In March, the United States issued a license to authorize the trade of Venezuelan gold and allow deals with Minarven, Venezuela's state-owned gold mining company. On 28 August 2026, President Donald Trump announced that the United States had reached an oil agreement with Venezuela's interim government, led by Delcy Rodríguez. Trump stated on his social media platform that the agreement would give the United States majority control over 65 billion barrels of proven oil reserves in Venezuela.
Sources: en.wikipedia.org
Mass spectrometry provides the most direct confirmation of molecular mass. Reversed-phase chromatography adds a retention-time signature that supports identity when compared against a reference standard. No single method is sufficient on its own.
Cool, dry conditions with desiccant are standard for the solid form. Long-term storage is usually at freezer temperatures, with short-term handling at refrigerator temperature. Vials are allowed to equilibrate before opening to prevent condensation.
Lipid conjugation increases hydrophobicity, which shifts chromatographic retention and can broaden peaks. It also creates additional related species when acylation is incomplete or the chain is oxidised. Methods are therefore developed to separate acylated and non-acylated forms explicitly.
尚未。它仍处于临床研究阶段，任何监管批准都取决于正在进行的试验结果和提交审评。可公开获取的信息以试验注册和会议摘要为主。